Dry age related macular degeneration. Senile Macular Degeneration( Atrophic)
Conditions
Interventions
Intervention 1: HESA-A wil be available as coated pills (996 mg) from Osveh pharmaceutical company. Drug will be given to treatment group as 50 mg bid in the first month then it will be given a week
Treatment - Drugs
Placebo
HESA-A wil be available as coated pills (996 mg) from Osveh pharmaceutical company. Drug will be given to treatment group as 50 mg bid in the first month then it will be given a week in a month as ab
Placebo will be given to control group as coated pills from Osveh pharmaceutical company in the dose of 50 mg/kg bid in the first month then it will be given a week in a month as above dose.
Sponsors
Hamedan university of medical sciences
Eligibility
Sex/Gender
All
Age
45 Years to 100 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria are mild or moderate loss of vision due to AMD including: non-central atrophy, RPE changes, multiple intermediate drusens (64-124 microns) or one large drusen ( diameter more than 124 microns) at least in one eye. Exclusion criteria are Corrected visual acuity less than 20/200, CNV or presence of any other ocular disease except mild cataract (1+)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Corrected visual acuity. Timepoint: before intervention and every month. Method of measurement: snellen chart. | — |
Secondary
| Measure | Time frame |
|---|---|
| Choroidal neovascularization. Timepoint: before intervention and every month. Method of measurement: fluorescein angiography and OCT of retina.;Ophthalmic or systemic side effects. Timepoint: every month in follow up period. Method of measurement: examination with slit lamp, super field lens and goldman tonometer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaeed Bashirian
Hamedan university of medical sciences
Outcome results
None listed